Solomon et al. examined whether a mobile application (app) for patients with rheumatoid arthritis integrated in the electronic health record would be used by patients and rheumatologists.
High-resolution computed tomography shows evidence of ILD.
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!
State by State—an Update on Proposed Legislation to Benefit Rheumatology
The state legislative tracker shows rheumatology-related bills the ACR is actively tracking in state legislatures across the country. It lists bills by issue area and state and is regularly updated to show each bill’s progression through the legislative process.
Advocate from Home for Medicare Payment Reform on Capitol Hill
As ACR leaders and volunteers visit Capitol Hill to advocate for stabilizing Medicare physician payment rates, you can join the effort from anywhere. Send your lawmakers a message today through the Legislative Action Center.
Research Review of Plant-Based Diet for Patients with Osteoarthritis or Rheumatoid Arthritis
About 30 years ago, early in his career as a rheumatologist, Dirkjan van Schaardenburg, PhD, says patients with osteoarthritis experienced terrible problems with inflammation. The landscape has improved to the point that “people can live with it now,” he says. But they still need help. For example, osteoarthritis affects 7% of the global population, according…
A Delicate Balance: How to Avoid Overmedicalization in Rheumatology
Rheumatologist Rachelle Buchbinder, AO, MBBS (Hons), MSc, PhD, discusses reducing overdiagnosis, overtreatment, low-value care and waste in medicine.
An Inside Look at the Advocacy Leadership Conference
At this year’s Hill Day, attendees will receive in-depth training on Medicare reimbursement and hear from Rep. Larry Bucshon, MD, (R-Ind.) about his perspective on the issue as a physician in Congress.
Advocacy Leadership Conference to Support Inflation-Linked Medicare Payment Increases
On May 7, ACR leaders from the Board of Directors, committees and more will to go to Capitol Hill and ask lawmakers to support legislation that would stabilize Medicare reimbursement for physicians.
CMS Updates the Medicare Conversion Factor
The Consolidated Appropriations Act, 2024 increased the Medicare conversion factor by 1.68% effective March 9, bringing it to $33.2875 for March 9–Dec. 31, 2024.
UnitedHealthcare Updates Reimbursement for Infliximab Biosimilars
On April 1, UnitedHealthcare updated reimbursement for infliximab biosimilars in response to concerns that formulary requirements are leaving practices underwater.
Poly-Refractory Rheumatoid Arthritis: An Uncommon Subset of a Difficult-to-Treat Disease
Difficult-to-treat rheumatoid arthritis (RA) is defined as the failure of two or more classes of biologic or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) to control active or progressive disease in patients with RA. Between 5 and 20% of patients with RA have difficult-to-treat RA.
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 246
- Next Page »